Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2024-01-03 Sale | 2024-01-05 4:50 pm | Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer | 5,843 | $29.46 | $172,135 | 54,372 (Direct) | View |
| 2023-01-04 Sale | 2023-01-06 5:26 pm | Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer | 2,574 | $37.21 | $95,779 | 25,687 (Direct) | View |
| 2022-01-01 Sale | 2022-03-03 8:00 pm | Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer | 1,051 | $112.24 | $117,964 | 48,117 (Direct) | View |
| 2021-11-05 Sale | 2021-11-09 6:08 pm | Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer | 2,400 | $132.72 | $318,535 | 188,791 (Direct) | View |
| 2021-10-14 Sale | 2021-10-15 7:02 pm | Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer | 2,400 | $128.44 | $308,249 | 191,191 (Direct) | View |
| 2021-09-21 Sale | 2021-09-23 5:48 pm | Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer | 2,400 | $149.81 | $359,544 | 193,591 (Direct) | View |
| 2021-08-30 Sale | 2021-09-01 7:32 pm | Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer | 2,400 | $158.04 | $379,300 | 195,991 (Direct) | View |
| 2021-08-09 Sale | 2021-08-11 4:50 pm | Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer | 2,400 | $164.05 | $393,720 | 198,391 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2024-03-01 Option Award | 2024-03-05 4:10 pm | N/A 2034-02-28 | Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer | 94,556 | $0 | 148,928 (Direct) | View |
| 2024-01-01 Exercise | 2024-01-03 5:34 pm | 2024-01-01 2031-03-02 | Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer | 3,187 | $0 | 63,404 (Direct) | View |
| 2023-03-01 Option Award | 2023-03-03 5:15 pm | N/A 2033-02-28 | Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer | 74,016 | $0 | 99,703 (Direct) | View |
| 2023-01-01 Exercise | 2023-01-04 8:33 pm | 2023-01-01 2031-03-02 | Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer | 3,187 | $0 | 34,637 (Direct) | View |
| 2022-03-01 Option Award(A) | 2022-03-04 9:01 pm | N/A 2032-02-28 | Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer | 20,203 | $0 | 20,203 (Direct) | View |
| 2022-03-01 Option Award | 2022-03-03 8:00 pm | N/A 2032-02-28 | Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer | 13,816 | $0 | 48,117 (Direct) | View |
| 2022-01-01 Exercise | 2022-03-03 8:00 pm | 2022-01-01 2031-03-02 | Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer | 3,187 | $0 | 48,117 (Direct) | View |
| 2021-11-05 Exercise | 2021-11-09 6:08 pm | N/A N/A | Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer | 2,400 | $12.62 | 188,791 (Direct) | View |
| 2021-11-05 Exercise | 2021-11-09 6:08 pm | N/A 2030-04-30 | Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer | 2,400 | $0 | 188,791 (Direct) | View |
| 2021-10-14 Exercise | 2021-10-15 7:02 pm | N/A N/A | Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer | 2,400 | $12.62 | 191,191 (Direct) | View |
| 2021-10-14 Exercise | 2021-10-15 7:02 pm | N/A 2030-04-30 | Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer | 2,400 | $0 | 191,191 (Direct) | View |
| 2021-09-24 Exercise | 2021-09-27 4:15 pm | N/A N/A | Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer | 7,923 | $12.62 | 193,591 (Direct) | View |
| 2021-09-24 Exercise | 2021-09-27 4:15 pm | N/A 2030-04-30 | Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer | 7,923 | $0 | 193,591 (Direct) | View |
| 2021-09-21 Exercise | 2021-09-23 5:48 pm | N/A N/A | Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer | 2,400 | $12.62 | 193,591 (Direct) | View |
| 2021-09-21 Exercise | 2021-09-23 5:48 pm | N/A 2030-04-30 | Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer | 2,400 | $0 | 193,591 (Direct) | View |
| 2021-08-30 Exercise | 2021-09-01 7:32 pm | N/A N/A | Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer | 2,400 | $12.62 | 195,991 (Direct) | View |
| 2021-08-30 Exercise | 2021-09-01 7:32 pm | N/A 2030-05-04 | Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer | 2,400 | $0 | 195,991 (Direct) | View |
| 2021-08-09 Exercise | 2021-08-11 4:50 pm | N/A N/A | Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer | 2,400 | $12.62 | 198,391 (Direct) | View |
| 2021-08-09 Exercise | 2021-08-11 4:50 pm | N/A 2030-05-04 | Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer | 2,400 | $0 | 198,391 (Direct) | View |
| 2021-03-03 Option Award | 2021-03-05 5:49 pm | N/A 2031-03-02 | Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer | 89,250 | $0 | 89,250 (Direct) | View |
| 2020-05-01 Option Award | 2020-05-05 4:49 pm | N/A 2030-04-30 | Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer | 200,000 | $0 | 200,000 (Direct) | View |